Annual Report 2023-24 | 81
Business Responsibility and 
Sustainability Reporting
Business Responsibility and Sustainability Reporting (BRSR) is a mandatory 
reporting requirement established by the Securities & Exchange Board of India 
(SEBI) for the top 1000 listed companies by market capitalization in India. The 
BRSR principles, which are based on the National Guidelines on Responsible 
Business Conduct (NGRBC—introduced by India’s Ministry of Corporate Affairs on 
15th March, 2019, to promote responsible business practices), encourage listed 
companies to adopt Sustainable Business Practices and disclose information 
about their Environmental, Social, and Governance (ESG) performance.
The Company aims to advance in its ESG journey to achieve its goals of becoming 
a sustainable and responsible corporate entity and hereby presents its BRSR for 
(Listing Obligations & Disclosure Requirements) Regulations, 2015.
Entero Healthcare Solutions Limited, established in 2018, is responsible for 
Distribution and Marketing of Pharmaceuticals, Surgical and other Healthcare 
& Allied products. Previously known as ‘Entero Healthcare Solutions Private 
Limited’, with effect from 25th August 2023, the Company converted into Public 
Limited Company and with effect from 16th February 2024, got listed on NSE 
and BSE.
As one of India’s largest and rapidly expanding healthcare and pharamceutical 
product distributors, the Company has earned recognition among the top three 
distributors in terms of revenue in FY 2021-22. With a widespread operational 
footprint spanning 540 districts and physical warehouses in 39 cities across 
India, the Company boasts the largest customer network among pharmaceutical 
distributors and a prominent presence among retail pharmacies. Notably, the 
Company achieved unprecedented operational growth from FY 2018-19 to 
FY 2021-22. Now listed, the Company is poised to disclose its BRSR for FY 2023-24 
in a consolidated manner, encompassing its subsidiaries.
82 | Annual Report 2023-24
Transforming Healthcare Delivery
BUSINESS RESPONSIBILTY AND SUSTAINABILITY REPORT
In this report, the words – ‘The Company’, ‘Entero’, ‘We’, ‘Our’ are used interchangeably to denote Entero Healthcare Solutions 
Limited and its subsidiaries
SECTION A: GENERAL DISCLOSURES
I. 
Details of the listed entity:
1. 
Corporate Identity Number (CIN) of the Listed Entity 
- 
L74999HR2018PLC072204
2. 
Name of the Listed Entity 
– 
Entero Healthcare Solutions Limited
3. 
Year of incorporation 
– 
2018
 
– 
 Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 
Mathura Road, Faridabad, Haryana- 121003
5. 
Corporate address 
– 
 605 / 606, 6th Floor, Trade Centre, 
Bandra Kurla Complex, Bandra (East), Mumbai – 400051
6. 
E-mail 
– 
co.sec@ehspl.com
7. 
Telephone 
– 
022-69019100 / 022-26529100
8. 
Website 
– 
www.enterohealthcare.com
9. 
Financial year for which reporting is being done 
– 
2023-24
10. 
 Name of the Stock Exchange(s) where shares are listed:
Name of the Exchange
Stock Code
BSE Ltd.
544122
National Stock Exchange of India Ltd.
ENTERO
11. 
Paid-up Capital 
– 
 43,49,37,670/-
12. 
Name and contact details (telephone, email address) of the 
– 
Mr. Jayant Prakash
 
person who may be contacted in case of 
 
Tel: 022-69019100
 
any queries on the BRSR report 
 
 Address: 
 
 605/606, 6th Floor, Trade Centre, Bandra Kurla Complex,
 
 
 
Bandra (East), Mumbai, 400051
13. 
 Reporting boundary 
– 
This report is prepared on a consolidated basis for Entero
 
Are the disclosures under this report made on a 
 
Healthcare Solutions Limited (“Entero”/“Company”/“We”),
 
standalone basis (i.e. only for the entity) or on a 
 
encompassing its 39 subsidiaries.
 
consolidated basis (i.e. for the entity and all the 
 
entities which form a part of its consolidated 
14. 
 Name of assurance provider 
– 
 Not Applicable for the reporting period as per SEBI 
Circular No. SEBI/HO/CFD/CFD-SEC-2/P/CIR/2023/122 
date- 12th July, 2023.
15. 
 Type of assurance obtained 
– 
 Not Applicable for the reporting period as per SEBI 
Circular No. SEBI/HO/CFD/CFD-SEC-2/P/CIR/2023/122 
date- 12th July, 2023.
Annual Report 2023-24 | 83
II. 
Products/services
16. 
Details of business activities (accounting for 90% of the turnover):
S. No. Description of Main Activity
Description of Business Activity
% of Turnover 
of the entity
1.
The Company and its subsidiaries are engaged 
in the Business of Distribution and Marketing of 
Pharmaceuticals, Surgical and other Healthcare 
and Allied products.
Distribution and Marketing of Pharmaceuticals, 
Surgical and other Healthcare and Allied products.
100.00
17. 
Products/ Services sold by the entity (accounting for 90% of the entity’s Turnover):
S. No. Product/ Service
NIC 
Code
% of Turnover 
contributed
1.
Distribution and Marketing of Pharmaceutical, Surgical and other Healthcare and Allied 
products.
46497
100.00 
III. 
Operations
Location
Number of plants
Total
National
Nil
105
105
International
Nil
Nil
Nil
19. 
Markets served by the entity:
 
a. 
Number of locations
Locations
Number
National (No. of States & UTs)
19 States
International (No. of Countries)
Nil
 
 
Not Applicable as per the operations.
 
c. 
 A brief on types of customers: The Company operates in B2B segment. The customer base of Entero Healthcare Solutions 
Limited and its subsidiaries, consists of various segments within the Healthcare industry. This segment includes Retail 
Pharmacies, Hospitals, and Institutions such as Clinics.
IV. 
Employees
20. Details as at the end of Financial Year:
 
a. 
Employees and workers (including differently abled):
S. No. Particulars
Total 
(A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
EMPLOYEES
1.
Permanent (D)
3,240
2,388
73.70
852
26.30
2.
Other than Permanent (E)
144
118
81.94
26
18.06
3.
Total employees (D + E)
4.
Permanent (F)
The Company does not have any workers.
5.
Other than Permanent (G)
6.
Total workers (F + G)
84 | Annual Report 2023-24
Transforming Healthcare Delivery
 
b. 
Differently abled Employees and workers:
S. No. Particulars
Total (A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
DIFFERENTLY ABLED EMPLOYEES
1.
Permanent (D)
The Company does not have any Differently abled Employees.
2.
Other than Permanent (E)
3.
Total differently abled employees (D + E)
4.
Permanent (F)
The Company does not have any Differently abled workers.
5.
Other than permanent (G)
6.
Total differently abled workers (F + G)
21. 
Participation/Inclusion/ Representation of women:
Total (A)
No. and percentage of Females
No. (B)
% (B / A)
Board of Directors
8
2
25.00
Key Management Personnel*
2
0
0.00
 
22. Turnover rate for permanent employees and workers (in percent):
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
37.84
36.40
37.45
46.22
47.31
46.52
42.79
47.12
44.02
Permanent Workers
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
23. (a) Names of holding / subsidiary / associate companies / joint ventures
S. No. Name of the holding/ subsidiary/ associate 
Indicate 
whether 
holding/Subsidiary/ 
Associate/ 
Joint 
Venture
% of 
shares 
held by 
listed 
entity
Does the entity indicated 
the Business Responsibility 
initiatives 
of 
the 
listed 
1.
R S M Pharma Private Limited
Subsidiary
100.00
Yes
2.
Jaggi Enterprises Private Limited
Subsidiary
100.00
Yes
3.
G.S.Pharmaceutical Distributors Private Limited
Subsidiary
100.00
Yes
4.
Novacare Healthcare Solutions Private Limited
Subsidiary
100.00
Yes
5.
Chhabra Healthcare Solutions Private Limited
Subsidiary
100.00
Yes
6.
Galaxystar Pharma Distributors Private Limited
Subsidiary
100.00
Yes
7.
Sundarlal Pharma Distributors Private Limited
Subsidiary
100.00
Yes
8.
Millennium Medisolutions Private Limited
Subsidiary
100.00
Yes
9.
Getwell Medicare Solution Private Limited
Subsidiary
 85.00
Yes
10.
Vasavi Medicare Solutions Private Limited
Subsidiary
100.00
Yes
Annual Report 2023-24 | 85
S. No. Name of the holding/ subsidiary/ associate 
Indicate 
whether 
holding/Subsidiary/ 
Associate/ 
Joint 
Venture
% of 
shares 
held by 
listed 
entity
Does the entity indicated 
the Business Responsibility 
initiatives 
of 
the 
listed 
11.
Avenues Pharma Distributors Private Limited
Subsidiary
100.00
Yes
12.
Chirag Medicare Solutions Private Limited
Subsidiary
100.00
Yes
13.
Chethana Healthcare Solutions Private Limited
Subsidiary
100.00
Yes
14.
Rada Medisolutions Private Limited
Subsidiary
100.00
Yes
15. 
Chethana Pharma Private Limited
Subsidiary
100.00
Yes
16.
SVMED Solutions Private Limited
Subsidiary
100.00
Yes
17.
CPD Pharma Private Limited
Subsidiary
100.00
Yes
18.
Sesha Balajee Medisolutions Private Limited
Subsidiary
100.00
Yes
19.
Barros Enterprises Private Limited
Subsidiary
100.00
Yes
20.
Calcutta Medisolutions Private Limited
Subsidiary
100.00
Yes
21.
Quromed Lifesciences Private Limited
Subsidiary
100.00
Yes
22.
Rimedio Pharma Private Limited
Subsidiary
100.00
Yes
23.
Sree Venkateshwara Medisolutions Private 
Limited
Subsidiary
100.00
Yes
24.
Chethana Pharma Distributors Private Limited
Subsidiary
100.00
Yes
25.
Curever Pharma Private Limited
Subsidiary
100.00
Yes
26.
Atreja Healthcare Solutions Private Limited
Subsidiary
100.00
Yes
27.
City Pharma Distributors Private Limited
Subsidiary
100.00
Yes
28.
Western Healthcare Solutions Private Limited
Subsidiary
100.00
Yes
29.
Swami Medisolutions Private Limited
Subsidiary
100.00
Yes
30.
New RRPD Private Limited
Subsidiary
100.00
Yes
31.
New Siva Agencies Private Limited
Subsidiary
100.00
Yes
32.
Zennx Software Solutions Private Limited
Subsidiary
100.00
Yes
33.
Sri Rama Pharmaceutical Distributors Private 
Limited
Subsidiary
100.00
Yes
34.
Sri Parshva Pharma Distributors Private Limited
Subsidiary
100.00
Yes
35.
Saurashtra Medisolutions Private Limited
Subsidiary
100.00
Yes
36.
SVS Lifesciences Private Limited
Subsidiary
100.00
Yes
37.
S.S. Pharma Traders Private Limited
Subsidiary
100.00
Yes
38.
Entero R.S. Enterprises Private Limited
Subsidiary
100.00
Yes
39.
Dhanvanthri Super Speciality Private Limited
Subsidiary
 80.00
Yes
VI. 
CSR Details
24. (i) 
Whether CSR is applicable as per section 135 of Companies Act, 2013:
 
 
 CSR is not applicable to Entero Healthcare Solutions Limited. However, it is applicable to its subsidiaries Chethana 
Pharma Pvt Ltd, Chirag Medicare Solutions Pvt. Ltd and R S M Pharma Pvt. Ltd.
 
(ii) 
Turnover – 3181.61 Million
 
(iii) Net worth – 16264.13 Million
86 | Annual Report 2023-24
Transforming Healthcare Delivery
VII. Transparency and Disclosures Compliances
25.  Complaints/ Grievance on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business 
Conduct:
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in Place 
(Yes/ No)
 
policy)
Number of 
complaints 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Number of 
complaints 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Communities
Yes
Nil
Nil
Not Applicable 
Nil
Nil
-
Investors 
(other than 
shareholders)
Yes, 
the 
Company 
has 
a 
Grievance 
Redressal 
Mechanism in place for its 
investors. We prioritize 
addressing and resolving 
Investor concerns promptly and 
effectively. To facilitate this, we 
have established a dedicated 
email ID: investor.grievance@
ehspl.com where investors can 
submit their grievances.
37
0
All complaints 
received were 
addressed 
within 
timeframes.
Nil
Nil
- 
Shareholders
Yes- Stakeholder’s Relationship 
Committee addresses the 
grievances. Further, the 
Complaints can be addressed 
at SEBI SCORES portal: 
https://www.scores.gov.in and 
Whistleblower policy (https://
w w w. e n t e r o h e a l t h c a r e .
com/investor/documents/
C o r p o r a t e _ G ove r n a n c e /
Policies/Vigil-Mechanism-&-
Whistle-Blower-Policy.pdf)
Nil
Nil
-
Nil
Nil
- 
Annual Report 2023-24 | 87
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in Place 
(Yes/ No)
 
policy)
Number of 
complaints 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Number of 
complaints 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Employees and 
workers
Yes- Employee’s Code of 
Conduct policy (Available 
on Intranet) addresses the 
grievances.
1
1
Compensation 
related issue 
which was 
amicably 
resolved 
Nil
Nil
Not 
Applicable 
Customers
Yes, The Company has 
established a Grievance 
Redressal Mechanism in place. 
Customers can reach out for 
support and resolution of 
their grievances by emailing 
us: info@enterohealthcare.
com; entero.drugsafety@
ehspl.com; customercare@
enterohealthcare.com 
Nil
Nil
Not Applicable 
Nil
Nil
Not 
Applicable 
Value Chain 
Partners
Yes, the Company has a 
Supplier Code of Conduct 
policy in place. This policy 
ensures that all partners 
within the value chain adhere 
to the highest standards of 
ethical conduct, environmental 
stewardship, and social 
responsibility.
Nil
Nil
Not Applicable 
Nil
Nil
Not 
Applicable 
88 | Annual Report 2023-24
Transforming Healthcare Delivery
26.  Overview of the entity’s material responsible business conduct issues pertaining to environmental and social matters that 
present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk 
1
S. No. Material issue 
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for identifying the risk/ 
opportunity
adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
1
Employee 
Welfare
Opportunity By investing in supportive 
workplace environments, we 
attract and retain top talent 
and enhance overall workforce 
morale. This focus on employee 
welfare not only fosters a loyal and 
motivated team but also positions 
the Company as a leader in the 
industry. Moreover, employee well-
being contributes positively to 
the Company’s reputation, driving 
higher customer satisfaction 
and, ultimately, greater business 
success. 
Not Applicable
Positive
2
GHG 
(Green House 
Gas) Emission
Risk
Greenhouse gas (GHG) emissions 
Distributor of healthcare products 
by potentially disrupting the 
Supply chain and increasing 
Operational costs. As Regulatory 
bodies worldwide impose stricter 
environmental 
regulations, 
Companies with high GHG 
emissions may face penalties, 
increased compliance costs and 
restrictions on their operations. 
Additionally, Climate Change 
driven by GHG emissions can 
lead to extreme weather events, 
which can damage infrastructure, 
delayed deliveries and disrupt the 
distribution network.
To mitigate these risks, we aim 
to implement strategies such 
transitioning to renewable 
energy sources and enhancing 
supply chain resilience through 
contingency planning.
Negative
* 
There 
was 
no 
impact 
in 
the 
reporting year 2023-
24.
Annual Report 2023-24 | 89
S. No. Material issue 
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for identifying the risk/ 
opportunity
adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
3
Business 
Ethics
Opportunity
opportunity to differentiate 
itself in a competitive market 
by adopting strong Business 
Ethics. By committing to Ethical 
practices, such as Transparent 
pricing, Fair labor conditions 
and Responsible sourcing of 
medical supplies, the Distributor 
can build a strong reputation for 
integrity and trustworthiness. 
Ensuring compliance with relevant 
regulations would avoid litigations 
and strengthen the corporate 
governance of the Company.
Not Applicable
Positive
4
Managing 
Risk
Managing Fleet fuel presents a 
risk due to various factors such as 
fuel consumption and the potential 
for environmental impact. These 
risks can result in increased 
operational costs, revenue losses, 
regulatory non-compliance and 
reputational damage.
To mitigate these risks, we 
aim to implement robust 
fuel management strategies, 
including monitoring Fuel 
technologies and conducting 
Regular audits. Additionally, 
c o n d u c t i n g  
R e g u l a r 
maintenance on Fleet vehicles, 
and promoting a culture of Fuel 
risks associated with Fleet fuel 
management.
Negative
* There was no 
impact in the 
reporting year 
2023-24.
5
Customer 
Welfare
Opportunity By prioritizing Customer welfare, 
we focus on providing high-quality 
products and services that meet 
the unique needs of healthcare 
facilities and patients, ultimately 
leading to improved patient 
outcomes and satisfaction. This 
fosters trust and loyalty among the 
customers, resulting in increased 
retention and referral business. 
Additionally, by actively engaging 
with our dealers & customers to 
understand market needs and 
preferences, we try to identify 
opportunities for innovation and 
continuous improvement, further 
enhancing the value we provide to 
our customers.
Not Applicable
Positive
90 | Annual Report 2023-24
Transforming Healthcare Delivery
SECTION B: MANAGEMENT AND PROCESS DISCLOSURES
Disclosure Questions
P2
P3
P7
Policy and management processes
Whether your entity’s policy/ policies cover each principle 
and its core elements of the NGRBCs. (Yes/No)
Yes
Yes
Yes
Yes
Yes
 Yes
Yes
Yes
Yes
 
b. 
Has the policy been approved by the Board? (Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
 
c. 
Web Link of the Policies, if available
 Please refer to the table below for the list of policies.
S. No. Name of policy
Link to Policy
Principle–Policy 
alignment
1
Policy for Determination 
of Materiality of any event/
information
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Policy-on-Materialit-of-Events.pdf 
P1
2
Dividend Distribution Policy
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Dividend-Distribution-Policy.pdf 
P1
3
Vigil Mechanism and Whistle 
Blower Policy
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Vigil-Mechanism-&-Whistle-
Blower-Policy.pdf 
P1
4
Policy on Materiality of Related 
Party Transactions
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Policy-On-Materiality-of-RPT.pdf 
P1, P4, P7
5
Corporate Social Responsibility 
Policy
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Corporate-Social-Responsibility-
Policy.pdf 
P8
6
Policy on Prevention of Sexual 
Harassment 
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Policy-on-Prevention-of-Sexual-
Harassment.pdf 
P5
7
Code of Prohibition of Insider 
Trading and Fair Disclosure of UPSI
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Code-for-Prohibition-of-Insider-
Trading-and-Fair-disclosure-of-UPSI.pdf 
P1
8
Archival Policy
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Archival-Policy.pdf 
P1
9
Code of Conduct for Independent 
Directors
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Code-of-Conduct-for-
Independent-Directors.pdf 
P1
10
Code of Conduct for the Board 
of Directors and the Senior 
Management 
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Code-of-Conduct-for-the-
Board-of-Directors-and-the-Senior-Management.pdf 
P1
11
Nomination and Remuneration 
Policy
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Nomination-and-Remuneration-
Policy.pdf 
P1, P5
12
Policy of Determining Material 
Subsidiaries 
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Policy-for-determining-Material-
Subsidiaries.pdf 
P1
13
Risk Management Policy
https://www.enterohealthcare.com/investor/documents/
Corporate_Governance/Policies/Risk-Management-Policy.pdf 
P1, P2
14
Policy for Evaluation of 
Performance of Board of Directors
Internal
P1
Annual Report 2023-24 | 91
S. No. Name of policy
Link to Policy
Principle–Policy 
alignment
15
Policy on Succession Planning for 
the Board and Senior Management
Internal
P1
16
Code of Conduct Policy
Internal
P1
17
Attendance Policy for HO
Internal
P3
18
Mediclaim Policy and GTA
Internal
P3
19
Local Conveyance
Internal
P3
20
Domestic Travel Policy
Internal
P3, P6
21
Internal
P1
22
Speak Up Policy
Internal
P3, P4, P5, P9
23
POSH Policy
Internal
P5
24
Grievance Redressal Policy
Internal
P3, P5
2. 
 Whether the entity has translated the policy into procedures. (Yes / No)
 
 Yes, policies are translated into procedures, and the company has formulated Standing Operating Procedures (SOPs) to 
implement these policies effectively.
3. 
 Do the enlisted policies extend to your value chain partners? (Yes/No)
 
No, as of now the policies do not extend to the Company’s Value Chain Partners.
Rainforest Alliance, and Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each 
principle.
 
 The Company and its subsidiaries are in the process of reviewing the impact of different standards on the operations post the 
Water conservation, Waste management, Air emission reduction and GHG mitigation. Moreover, the Company prioritizes the 
well-being of its employees and workers through rigorous Health and safety practices. It upholds the values of Ethics and 
Transparency in its workforce, followed by a robust governance framework.
not met.
 
 As the Company along with its subsidiaries is still evolving in terms of its ESG journey – we endeavour to set targets in coming 
years.
7. 
 Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and 
achievements
 
 I am pleased to present our Company’s Inaugural Business Responsibility and Sustainability Report (BRSR) since our listing 
in February 2024. As we embark on our journey into the realm of Environment, Social and Governance (ESG) considerations, 
particularly within the Distributions and Marketing of Pharmaceuticals, Surgical and other Healthcare and Allied products, we 
targets to reduce our environmental impact, enhance workplace diversity and safety, and improve governance transparency and 
accountability. While we acknowledge that this marks merely the beginning of our ESG journey, we are dedicated to continuous 
improvement and meaningful engagement with stakeholders as we strive for sustainable growth and value creation.
Mr. Prabhat Agrawal
Managing Director & CEO
92 | Annual Report 2023-24
Transforming Healthcare Delivery
8. 
Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy(ies).
 
Mr. Prabhat Agrawal
 
Managing Director & CEO
issues? (Yes / No). If yes, provide details.
 
No
10. 
Details of Review of NGRBCs by the Company:
Indicate whether review was under taken 
by Director / Committee of the Board/  
Any other Committee
Frequency 
(Annually/ Half yearly/ Quarterly/ 
Any other – please specify)
P2
P3
P7
P2
P3
P7
Performance against Above 
policies and follow up action
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Annually
Compliance with statutory 
requirements of relevance 
to the principles, and 
compliances
The Company strictly adheres to all legal 
and statutory standards and requirements, 
ensuring full compliance in all aspects.
11. 
 Has the entity carried out independent 
assessment/ evaluation of the working of its 
policies by an external agency? (Yes/No). 
If yes, provide name of the agency.
P 2
P 3
P 7
implementation and effectiveness of policies, emphasizing their 
and revise policies, with ultimate approval granted by Management or 
the Board. Internal auditors and Regulatory authorities scrutinize the 
processes and compliance measures, if necessary.
12. 
If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated:
Questions
P 2
P 3
P 7
The entity does not consider the Principles material to its business (Yes/No)
Not Applicable as the Company policies are 
compliant with all the principles.
The entity is not at a stage where it is in a position to formulate and 
available for the task (Yes/No)
Annual Report 2023-24 | 93
Essential Indicators
Segment
Total Number 
of training and 
awareness 
programmes 
held
Topics/ principles covered under the training and its 
impact
% age of persons 
in respective 
category covered 
by the awareness 
programmes
Board of Directors
1
1. 
 Overview of Corporate Governance Framework 
applicable to a Listed Company.
2. 
Key Compliance obligations under LODR.
3. 
 Compliance obligations in relation to Related Party 
Transactions.
4. 
 Compliance obligations in respect of reporting of 
Material Events and Information under Regulation 
30 of LODR.
5. 
 Compliance obligations in respect of Insider Trading 
under SEBI PIT Regulations.
6. 
 Disclosure obligations on the promoters under SEBI 
takeover code.
7. 
Compliance of Secretarial Standards.
8. 
Business related Induction programmes.
100.00
1
1. 
 Overview of Corporate Governance Framework 
applicable to a Listed Company.
2. 
Key Compliance obligations under LODR.
3. 
 Compliance obligations in relation to Related Party 
Transactions.
4. 
 Compliance obligations in respect of reporting of 
Material Events and Information under Regulation 
30 of LODR.
5. 
 Compliance obligations in respect of Insider Trading 
under SEBI PIT Regulations.
6. 
 Disclosure obligations on the promoters under SEBI 
takeover code.
7. 
Compliance of Secretarial Standards.
100.00
Employees other than 
4
periodic Fire Mock Drill. 
100.00
Not Applicable as the Company does not have any workers
94 | Annual Report 2023-24
Transforming Healthcare Delivery
disclosed on the entity’s website)
Monetary
NGRBC Principle
Name of the regulatory/
enforcement agencies/
Amount 
(in )
Brief of the Case
Has an appeal 
(Yes/No)
Penalty/Fine
Nil
Settlement
Compounding Fee*
Principle 1
Reserve Bank of India (RBI)
47,39,235
Delay in 
Downstream 
Investments (DI 
under FEMA) rules
No
Imprisonment
No instances of imprisonment or punishment were applicable.
Punishment
3. 
 Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or 
non-monetary action has been appealed.
Case Details
No Appeal or Revision were preferred, hence not applicable.
4. 
 Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a 
web-link to the policy.
stance against any form of Corruption. This clause serves as a guiding principle for all employees, emphasizing the importance 
of Ethical conduct in our business dealings. We maintain strict adherence to this Anti-bribery provision, ensuring that our 
operations are conducted with Integrity and Transparency.
5. 
 Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law enforcement 
agency for the charges of bribery/ corruption:
Directors
Nil
KMPs
Employees
Workers
Number
Remarks
Number
Remarks
Number of complaints received in relation to issues 
In both reporting years, the Company and its subsidiaries have not 
Number of complaints received in relation to issues 
Annual Report 2023-24 | 95
Corruption, Fines, Penalties, or Actions taken by Regulators, Law enforcement agencies or Judicial institutions. As a result, 
there were no instances that required corrective action or investigation in this regard.
8. 
Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:
Number of days of accounts payables
21
23
9. 
Open-ness of Business
 
 
Parameter
Metrics
Concentration 
of Purchases
a. 
Purchases from Trading houses as % of total purchases
Not Applicable as per 
the business operations.
b. 
Number of trading houses where purchases are made from
c. 
 Purchases from top 10 trading houses as % of total 
purchases from trading houses
Concentration 
of Sales
a. 
Sales to dealers/distributors as % of total sales
100.00
100.00
b. 
Number of dealers/distributors to whom sales are made
 89,800+ Customer 
Count*
84,800+ Customer 
Count*
c. 
 Sales to top 10 dealers/distributors as % of total sales to 
dealers/distributors
6.83
4.94 
Share of 
RPTs in
a. 
 Purchases (Purchases with related parties/Total 
Purchases)
8.62
4.57
b. 
Sales (Sales to related parties/Total Sales)
8.15 
4.25
c. 
 Loans & advances (Loans & advances given to related 
parties/ Total loans & advances)
100.00
100.00
d. 
 Investments (Investments in related parties/ Total 
Investments made)
100.00
100.00
Leadership Indicators
Total number of awareness 
programmes held
Topic/principles covered 
under the training
% age of value chain partners covered (by value of 
business done with such partners) that were assessed
No Awareness programs have been conducted for the Value Chain Partners of the entity and its subsidiaries to date.
 
If yes, provide details of the same.
and Ethical decision-making, ensuring that the Board’s actions uphold the interests of all stakeholders.
96 | Annual Report 2023-24
Transforming Healthcare Delivery
PRINCIPLE 2:
BUSINESSES SHOULD PROVIDE GOODS AND SERVICES IN A MANNER THAT IS SUSTAINABLE AND 
SAFE
Essential Indicators
social impacts of product and processes to total R&D and capex investments made by the entity, respectively.
Details of Improvements in environmental and social impacts
R&D
The Company and its subsidiaries aspire to improve its Environmental and Social impact on their business 
processes by various activities and is an integral part of their operations. Therefore, the investments are not 
Capex
2. 
a. 
Does the entity have procedures in place for sustainable sourcing? (Yes/No)
 
 
 The Entity’s approach of directly sourcing products from Pharmaceutical Manufacturers or Registered dealers or the CFA 
(Carrying and Forwarding Agents) ensures a high level of legitimacy and quality control in the procurement process. Even 
 
b. 
If yes, what percentage of inputs were sourced sustainably?
 
 
Not Applicable. As there is no formal procedure for Sustainable sourcing.
3. 
 Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) 
Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
 
 Our Company and its subsidiaries place a strong emphasis on responsible Waste Management, although we currently 
handle E-waste or Hazardous waste, we responsibly manage other waste types through Municipal collection services. Our 
commitment lies in minimizing waste generation and adopting environmentally sustainable practices. Continuously striving 
for improvement, we dedicate ourselves to aligning our waste management processes with Industry Best Practices and 
Regulatory standards.
4. 
 Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, whether the waste 
collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, 
provide steps taken to address the same.
 
No, Extended Producer Responsibility (EPR) is not applicable to the Company and its subsidiaries business operations.
Leadership Indicators
1. 
 Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or 
for its services (for service industry)? If yes, provide details in the following format?
NIC 
Code
Name of 
Product/Service
% of total 
Turnover 
Contributed
Boundary for which the 
Life Cycle Perspective 
/ Assessment was 
conducted
 
by independent 
external agency 
(Yes/No)
Results communicated in 
public domain (Yes/No)  
The Company and its subsidiaries operate as wholesale distributors of pharmaceuticals, surgical and other healthcare and 
allied products. The Company and its subsidiaries are not liable for any manufacturing/processing so LCA is not applicable 
to the Company.
describe the same along-with action taken to mitigate the same.
Name of Product/ Service
Description of the risk/ concern
Action Taken
Not Applicable as the Company and its subsidiaries are not involved in manufacturing/processing of any goods.
Annual Report 2023-24 | 97
3. 
 Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) 
or providing services (for service industry).
Indicate input material
The percentage of recycled or reused input materials to total materials used in production is not applicable to the Company 
and its subsidiaries operations, as it functions as a wholesale distributor of healthcare, pharmaceuticals, surgical and other 
allied products and do not engage in any manufacturing/processing activities.
4. 
 Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely 
disposed, as per the following format:
Recycled
Safely 
Disposed 
Recycled
SafelyDisposed
Plastics (including packaging)
Not applicable to the Company and its subsidiaries 
considering their nature of operations.
E-waste
Hazardous Waste
Other waste
5. 
Reclaimed products and their packaging materials (as percentage of products sold) for each product category
Indicate product 
category
Reclaimed products and their packaging materials 
(as percentage of products sold) for each product category
Not Applicable 
98 | Annual Report 2023-24
Transforming Healthcare Delivery
PRINCIPLE 3:
THOSE IN THEIR VALUE CHAINS
Essential Indicators
1. 
a. 
Details of measures for the well-being of employees:
% of employees covered by
Total 
(A)
Health Insurance
Accident 
Insurance
Maternity 
Paternity 
Day Care 
facilities
Number 
(B)
% 
(B/A)
Number 
(C)
% 
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Permanent Employees
Male
2,388
447
18.71
447
18.71
0
0.00
447
18.71
0
0.00
Female
852
49
5.75
49
5.75
49
5.75
0
0
0
0.00
Total*
Other than Permanent Employees
Male
118
0
0.00
0
0.00
0
0.00
0
0.00
0
0.00
Female
26
0
0.00
0
0.00
0
0.00
0
0.00
0
0.00
Total
 
b. 
Details of measures for the well-being of workers:
% of workers covered by
Total 
(A)
Health Insurance
Accident 
Insurance
Maternity 
Paternity 
Day Care 
facilities
Number 
(B)
% 
(B/A)
Number 
(C)
% 
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Male
0
0
0.00
0
0.00
0
0.00
0
0.00
0
0.00
Female
0
0
0.00
0
0.00
0
0.00
0
0.00
0
0.00
Total
Male
0
0
0.00
0
0.00
0
0.00
0
0.00
0
0.00
Female
0
0
0.00
0
0.00
0
0.00
0
0.00
0
0.00
Total
 
c. 
 Spending on measures towards well-being of employees and workers (including permanent and other than permanent) 
in the following format:
Cost incurred on well-being measures as a % of total revenue 
of the company
0.02
0.03
Annual Report 2023-24 | 99
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as 
a % of total 
workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as 
a % of total 
workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
PF
100.00
0.00
Y
100.00
0.00
Y
Gratuity
100.00
0.00
NA 
100.00
0.00
NA
ESI
100.00
0.00
NA
100.00
0.00
NA
3. 
Accessibility of workplaces
 
 
 
 The Company and its subsidiaries are actively working to create a more inclusive and accessible workspace for all employees. 
4. 
 Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-
link to the policy.
our existing Code of Conduct Policy serves to foster principles of fairness and non-discrimination. This comprehensive policy 
promotes a workplace culture where all individuals are treated equitably and respectfully. We strive to create an inclusive 
environment where everyone has the opportunity to thrive and contribute to their fullest potential.
5. 
Return to work and Retention rates of permanent employees and workers that took parental leave.
Permanent Employees
Permanent workers
Gender
Return to work rate
Retention rate
Return to work rate
Retention rate
Male
-
-
-
Female
-
-
Total
-
-
6. 
 Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? 
If yes, give details of the mechanism in brief.
Not Applicable
Not Applicable
Permanent Employees
The Company’s POSH (Prevention of Sexual Harassment) and The Employee Handbook 
are designed to provide robust mechanisms for employees to report grievances safely 
addressing issues like Harassment, Discrimination and Unethical practices. Employees 
can report grievances through multiple channels, including direct emails to the Human 
Resources team, or by contacting their Reporting Manager.
Other than Permanent Employees
100 | Annual Report 2023-24
Transforming Healthcare Delivery
7. 
Membership of employees and worker in association(s) or Unions recognized by the listed entity:
Category
Total employees 
/ workers in 
respective 
category (A)
No. of employees/ 
workers in respective 
of association(s) or 
Union (B)
% 
(B/A)
Total employees 
/ workers in 
respective 
category (C)
No. of employees/ 
workers in respective 
of association(s) or 
Union (D)
% 
(D/C)
Total Permanent 
Employees
associations or unions.
Male
Female
Total Permanent 
Male
Female
8. 
Details of training given to employees and workers:
Total 
(A)
On Health and 
Safety measures
On Skill 
upgradation
Total 
(D)
On Health and 
Safety measures
On Skill 
upgradation
No. 
(B)
%  
(B/A)
No. 
(C)
%  
(C/A)
No. 
(E)
% 
(E/D)
No. 
(F)
% 
(F/D)
Employees
Male
2,506
0
0.00
0
0.00
2,324
0
0.00
0
0.00
Female
878
0
0.00
0
0.00
864
0
0.00
0
0.00
Total
Male
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Female
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Total
9. 
Details of performance and career development reviews of employees and worker:
Category
Total (A)
No. (B)
% (B/A)
Total (C)
No. (D)
% (D/C)
Employees
Male
2,506
2,506
100.00
2,324
2,324
100.00
Female
878
878
100.00
864
864
100.00
Total
Workers
Male
0
0
0.00
0
0
0.00
Female
0
0
0.00
0
0
0.00
Total
Annual Report 2023-24 | 101
10. 
Health and safety management system:
 
 
 The Company and its subsidiaries currently do not have an Occupational Health and Safety Management System in 
of such a system. Moving forward, the Company and its subsidiaries are committed to exploring the implementation 
of a comprehensive occupational health and safety management system. We aim to develop and establish appropriate 
procedures and protocols to ensure the safety and well-being of our employees. This initiative will be a priority for us as 
we strive to align with best practices and enhance our overall sustainability efforts.
 
 
 Currently, the Company and its subsidiaries do not have established procedures for identifying work-related hazards 
and assessing risks on either a routine or non-routine basis. However, recognizing the importance of such processes 
for ensuring workplace safety and compliance, the Company and its subsidiaries are committed to developing and 
actively working towards formulating and integrating these safety measures into our operational practices soon.
risks. (Y/N)
 
 
 The Company and its subsidiaries do not have a formal procedure in place for workers to report work-related hazards and 
remove themselves from such risks. However, we are committed to developing and implementing such a procedure in the 
near future. We aim to establish a robust process that ensures the safety and well-being of our employees.
 
 
 The Employees of the Company and its subsidiaries do not have access to Non-occupational Medical and Healthcare 
services. However, the Company and its subsidiaries have demonstrated its commitment to employee’s well-being 
by organizing Health Camps, Dental Camps and Cardiovascular Sessions. These initiatives highlight our dedication to 
promoting the health and wellness of our employees, even in the absence of a formal procedure for Non-occupational 
Medical services.
11. 
Details of safety related incidents, in the following format:
Safety Incident/Number
Category
Lost Time Injury Frequency Rate (LTIFR)  
(per one million-person hours worked)
Employees
No such incidents occurred in both the 
reporting years.
Workers
Total recordable work-related injuries
Employees
Workers
No. of fatalities
Employees
Workers
High consequence work-related injury or ill-health 
(excluding fatalities)
Employees
Workers
12. 
Describe the measures taken by the entity to ensure a safe and healthy work place.
 
 The Company and its subsidiaries have ensured all equipment and processes for activities in the warehouses to be carried out 
in a safe and healthy manner. The Company and its subsidiaries are not involved in any manufacturing/processing activities.
102 | Annual Report 2023-24
Transforming Healthcare Delivery
13. 
Number of Complaints on the following made by employees and workers:
Filed during  
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Working Conditions
There were no complaints regarding working conditions for health and safety during either of 
the reporting years.
Health & Safety
14. 
Assessments for the year:
 
(by entity or statutory authorities or third parties)
Health and safety practices
No assessments were conducted during the reporting year.
Working Conditions
risks / concerns arising from assessments of health & safety practices and working conditions.
 
Not Applicable, as no such incidents occurred during the reporting year.
Leadership Indicators
1. 
 Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N)  
(B) Workers (Y/N)
times, the Company along with its subsidiaries extends Life Insurance coverage and Compensatory packages in the event of 
the death of an employee.
2. 
 Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value 
chain partners.
 
 The Company and its subsidiaries ensure that statutory dues are deducted and deposited by its value chain partners through a 
By meticulously reviewing them, we verify that all necessary deductions have been accurately calculated and remitted to the 
appropriate authorities. This proactive approach helps us to mitigate the risk of non-compliance and ensures that statutory 
obligations are met in a timely and accurate manner throughout the value chain, ensuring sustainability.
3. 
 Provide the number of employees / workers having suffered high consequence work- related injury / ill-health / fatalities 
(as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable employment or whose 
family members have been placed in suitable employment:
Total no. of 
affected employees/workers
No. of employees/workers that are 
rehabilitated and placed in suitable 
employment or whose family members 
have been placed in suitable employment
Employees
Nil
Nil
Nil
Nil
Workers
Nil
Nil
Nil
Nil
Annual Report 2023-24 | 103
4. 
 Does the entity provide transition assistance programs to facilitate continued employability and the management of career 
endings resulting from retirement or termination of employment? (Yes/ No)
 
 The Company and its subsidiaries, at present, do not provide any transition assistance to its employees. While we acknowledge 
the importance of supporting individuals during career transitions, we have not yet implemented formal programs for this 
purpose. However, we are open to exploring options to better assist employees in navigating such transitions in the future.
5. 
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such partners) that were assessed
Health and safety 
practices
As the Company got listed on 16th Feb 2024. The Company was not able to institutionalise the 
interactions with Value Chain Partners as per BRSR, howsoever, The Company from the time of its 
inception has been working on process enhancement initiatives with its value chain partners. The 
Company has robust complaint redressal mechanism for its value chain partners.
Working Conditions
assessments of health and safety practices and working conditions of value chain partners.
 
Not Applicable as no such incidents occurred during the reporting year.
104 | Annual Report 2023-24
Transforming Healthcare Delivery
BUSINESSES SHOULD RESPECT THE INTERESTS OF AND BE RESPONSIVE TO ALL ITS 
Essential Indicators
1. 
Describe the processes for identifying key stakeholder groups of the entity.
 
 Identifying key Stakeholder groups of the Entity and its subsidiaries involves a structured process that considers various 
relationship with the organization, including Employees, Customers, Suppliers and Investors. For Employees, methods such as 
personal interactions, mobile communication, emails, meetings and trainings are utilized to maintain regular communication 
and address their needs and concerns, thereby fostering a positive work environment and ensuring their engagement and 
timely updates on service offerings and addressing any critical incidents promptly to maintain customer satisfaction and 
requirements, focusing on information impacting share prices and investor interests.
Stakeholder 
Group
Vulnerable & 
Group (Yes/No)
Channels of Communication 
Frequency of 
engagement 
(Annually/ Half yearly/ 
Quarterly/ others – 
please specify)
Purpose and scope of 
engagement including 
key topics and concerns 
raised during such 
engagement
Employees
No
Personal Interaction, Mobile, 
E-mail, Meetings, Trainings
Regularly, 
Need basis
Regular updates on 
business, periodic 
interactions for 
relationship building
Customers
No
Personal Interaction, Mobile, 
E-mail
Need basis
Service offering 
updates, critical incident 
reporting
Suppliers
No
Personal Interaction, Mobile
Annually, Quarterly, 
Need basis
Business continuity 
Investors/ 
Shareholders
No
Media releases, Investor meets, 
Annual General Meeting
Annually, Quarterly, 
Need basis
Shares prices and 
Investors interests
Regulators
Yes
Website, stock exchange 
dissemination, and submission of 
document on web portal
Ongoing as on 
Need basis
Compliance requirement
Community
Yes
Website, conference
Ongoing
Product awareness, 
interaction for 
relationship building
Leadership Indicators
1. 
 Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics 
or if consultation is delegated, how is feedback from such consultations provided to the Board.
 
 While currently, there are no formal processes in place for consultation between stakeholders and the Board on ESG topics, it 
BRSR, there is a recognition of the importance of establishing such processes in the future. Feedback from stakeholder 
consultations, once initiated, will be carefully documented and provided to the Board for consideration. Moving forward, the 
Company and its subsidiaries are committed to developing robust processes for stakeholder engagement, ensuring that their 
perspectives and concerns are effectively integrated into decision-making processes related to Economic, Environmental 
and Social matters.
Annual Report 2023-24 | 105
topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were 
incorporated into policies and activities of the entity.
 
 Currently, the Company and its subsidiaries do not have formal consultation processes between stakeholders and the Board 
forward involves developing robust stakeholder engagement processes to integrate their perspectives into decision-making 
on Economic, Environmental and Social matters.
3. 
 Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized 
stakeholder groups.
 
 While there have been no instances of engagement with or actions taken to address the concerns of vulnerable/ marginalized 
stakeholder groups so far, we recognize the importance of such engagement. We are committed to proactively seeking 
opportunities to address their concerns and prioritize their well-being in our decision-making processes. Moving forward, 
we aim to take concrete actions to support these stakeholder groups, ensuring their voices are heard and their needs are 
addressed effectively.
106 | Annual Report 2023-24
Transforming Healthcare Delivery
BUSINESSES SHOULD RESPECT AND PROMOTE HUMAN RIGHTS
Essentials Indicators
1. 
 Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following 
format:
Category
Total 
(A)
No. of employees/ 
workers covered (B)
% 
(B/A)
Total 
(C)
No. of employees/ 
workers covered (D)
% 
(D/C)
Employees
Permanent
3,240
3,240
100.00
3,041
3,041
100.00
Other than permanent
144
144
100.00
147
147
100.00
Total Employees
Permanent
0
0
0.00
0
0
0.00
Other than permanent
0
0
0.00
0
0
0.00
2. 
Details of minimum wages paid to employees and workers, in the following format:
Category
Total
(A)
Equal to 
More than 
Total
(D)
Equal to 
More than 
No. (B)
% (B/A)
No. (C)
% (C/A)
No.(E)
% (E/D)
No. (F)
% (F/D)
Employees
Permanent
3,240
342
10.56
2,898
89.44
3,041
340
11.18
2,701
88.82
Male
2,388
148
6.20
2,240
93.80
2,195
136
6.20
2,059
93.80
Female
852
194
22.77
658
77.23
846
204
24.11
642
75.89
Other than 
Permanent
144
144
100.00
0
0.00
147
147
100.00
0
0.00
Male
118
118
100.00
0 
0.00
129
129
100.00
 0
0.00
Female
26
26
100.00
0 
0.00
18
18
100.00
 0
0.00
Permanent
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Male
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Female
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Other than 
Permanent
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Male
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Female
0
0
0.00
0
0.00
0
0
0.00
0
0.00
Annual Report 2023-24 | 107
3. 
Details of remuneration/salary/wages, in the following format:
 
a. 
Median remuneration/wages:
Male
Female
Number
Median remuneration/ Salary/ 
(in /year)
Number
Median remuneration/ Salary/ 
(in /year)
Board of Directors (BoD)
2
3,14,95,801
Refer to the note given below
Key Managerial Personnel*
2
 1,10,97,500
Nil, as there are no female KMPs
Employees other than BoD 
and KMP
443
4,82,796
49
5,77,172
Workers
Nil
 
Gross wages paid to females as % of total wages
16.55
17.33
4. 
 Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or 
contributed to by the business? (Yes/No)
Grievances Redressal and a Whistle Blower Policy (available on Intranet) in place to ensure a positive and safe work environment.
5. 
Describe the internal mechanisms in place to redress grievances related to human rights issues
 
 The Company’s POSH (Prevention of Sexual Harassment) and Whistleblower Policies are designed to provide robust 
environment by addressing issues like Harassment, Discrimination and Unethical practices. Employees can report grievances 
through multiple channels, including direct emails to the Human Resources team, or by contacting their Reporting Manager. 
This multi-faceted approach ensures that employees feel supported, fostering a culture of transparency and trust within the 
Company.
6. 
Number of Complaints on the following made by employees and workers:
Filed during 
the year
Pending 
resolution at the 
end of the year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of the year
Remarks
Sexual harassment
Not Applicable, as no such incidents occurred in both reporting years.
Discrimination at workplace
Child Labour
Forced Labour/ Involuntary 
Labour
Wages
Other Human Rights related 
issues
108 | Annual Report 2023-24
Transforming Healthcare Delivery
the following format:
Total Complaints reported under Sexual Harassment on of Women at 
Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)
Not Applicable, as no such incidents 
occurred in both reporting years.
Complaints on POSH as a % of female employees / workers
Complaints on POSH upheld
8. 
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases
 
 According to the Grievance Redressal Policy (available on Intranet), any information regarding employees reporting violations 
against the complainant, ensuring a safe and supportive environment for those who come forward.
9. 
Do human rights requirements form part of your business agreements and contracts?
 
 Yes, Human rights requirements are integral to the Company’s Code of Conduct and are explicitly included in all Business 
Agreements and Contracts. This commitment ensures that all parties involved uphold the highest standards of Human 
Rights practices. Continuous monitoring is being done internally to ensure adherence to these commitments, reinforcing the 
Company’s and its subsidiaries’ dedication to Human Rights.
10. 
Assessments for the year:
 
(by entity or statutory authorities or third parties)
Child Labour
The Company and its subsidiaries did not conduct such assessments during the reporting 
year. However, there is a commitment to conduct these assessments in the near future.
Forced/involuntary labour
Sexual Harassment
Discrimination at workplace
Wages
assessments at Question 10 above.
 
Not applicable since the Company and its subsidiaries did not conduct such assessments during the reporting year.
Leadership Indicators
 
 Currently, there are no set procedures for addressing human rights grievance. However, we are committed to considering the 
implementation of such procedures in the future.
2. 
Details of the scope and coverage of any Human rights due-diligence conducted.
 
 During the reporting period, no Human Rights Due Diligence was conducted. However, the Company and its subsidiaries intend 
to conduct such due diligence in the future. This process will involve comprehensively assessing the scope and coverage to 
ensure a thorough examination of human rights aspects across the Company and its subsidiaries.
with Disabilities Act, 2016?
 
 The Company and its subsidiaries are actively working to create a more inclusive and accessible workspace for all employees. 
Annual Report 2023-24 | 109
4. 
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such partners) 
that were assessed
Sexual Harassment
The Company and its subsidiaries have not conducted an assessment of value chain 
committed to considering the implementation of procedures for assessing value 
chain partners in the future.
Discrimination at workplace
Child Labour
Forced Labour / Involuntary Labour
Wages
assessments at Question 4 above.
 
Not applicable since no assessment of value chain partners has been conducted by the Company and its subsidiaries.
110 | Annual Report 2023-24
Transforming Healthcare Delivery
ENVIRONMENT
Essential Indicators
1. 
Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:
Parameter
 
 
From renewable sources
Total electricity consumption (A) 
0
0
Total fuel consumption (B) 
0
0
Energy consumption through other sources (C) 
0
0
Total Energy consumption from renewable sources (A+B+C)
0
0
Total electricity consumption (D) 
1,69,76,656.80
 1,45,08,478.80 
Total fuel consumption (E) 
7,86,057.41
15,76,642.36
Energy consumption through other sources (F) 
0
0
Total energy consumed (A+B+C+D+E+F)
Energy intensity per rupee of turnover 
(Total energy consumption/ Revenue from Operations)–Megajoules/
0.00045
0.00049
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP)  (Total energy consumed / Revenue from operations adjusted for PPP)- 
Megajoules/
0.0101
0.0108
Energy intensity in terms of physical output**
-
-
Energy intensity (optional) – the relevant metric may be selected by the entity**
-
-
 
 There hasn’t been an external review or analysis conducted to assess various aspects of our operations, performance, or 
compliance with standards or regulations.
Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been 
achieved. In case targets have not been achieved, provide the remedial action taken, if any.
 
 Our facilities at the Company along with its subsidiaries are not included in the Perform, Achieve and Trade (PAT) Scheme 
initiated by the Government of India. Consequently, our sites are not subject to the regulations and requirements of the PAT 
conservation standards.
Annual Report 2023-24 | 111
3. 
Provide details of the following disclosures related to water, in the following format:
Parameter
Water withdrawal by source (in kilolitres) 
(i) 
Surface water
0
0
(ii) 
Groundwater
0
0
(iii) Third party water
40,608.00
38,256.00
(iv) Seawater / desalinated water
0
0
(v) 
Others
0
0
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
Total volume of water consumption (in kilolitres) 
Water intensity per rupee of turnover 
(Water consumed / Revenue from operations)–Kilolitres/
0.00000010
0.00000012
Water Intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP) (Total water consumption / Revenue from operations adjusted for PPP)
0.0000023
0.0000026
Water intensity in terms of physical output**
-
-
Water intensity (optional) – the relevant metric may be selected by the entity**
-
-
 
 
 
 There hasn’t been an external review or analysis conducted to assess various aspects of our operations, performance, or 
compliance with standards or regulations.
4. 
Provide the following details related to water discharged
Parameter
Water discharge by destination and level of treatment (in kilolitres) 
(i) 
To Surface water 
0
0
 
- 
No treatment 
0
0
 
- 
With treatment – please specify level of treatment
0
0
(ii) 
To Groundwater 
0
0
 
- 
No treatment 
0
0
 
- 
With treatment – please specify level of treatment 
0
0
(iii) To Seawater
0
0
 
- 
No treatment
0
0
 
- 
With treatment – please specify level of treatment
0
0
(iv) Sent to third-parties
0
0
 
- 
No treatment 
36,547.20
34,430.40
 
- 
With treatment – please specify level of treatment
0
0
(v) 
Others
0
0
 
- 
No treatment
0
0
 
- 
With treatment – please specify level of treatment
0
0
Total water discharged (in kilolitres) 
 
 No external review or analysis has been conducted to assess various aspects of our operations, performance, or compliance 
with standards and regulations.
112 | Annual Report 2023-24
Transforming Healthcare Delivery
5. 
 Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.
 
 The Company and its subsidiaries have made commendable strides in environmental stewardship, particularly through the 
implementation of rainwater harvesting initiatives. Although we have prioritized sustainable water management practices, 
rented. However, the focus on rainwater harvesting highlights our dedication to conserving water resources and reducing its 
a proactive stance on sustainability. The Company and its subsidiaries remain open to exploring additional eco-friendly 
solutions to further enhance its environmental performance and positively impact the communities we serve.
6. 
Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:
Parameter 
Please specify unit 
NOx 
The Company and its subsidiaries operate without generating any 
air emissions, demonstrating their commitment to environmental 
responsibility and ensuring clean air for surrounding communities.
SOx 
Particulate matter (PM) 
Persistent organic pollutants (POP) 
Volatile organic compounds (VOC)
Hazardous air pollutants (HAP) 
Others – please specify 
 
 
No independent assessment, evaluation, or assurance has not been carried out by an external agency.
7. 
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:
Parameter
Unit
Total Scope 1 emissions 
Refrigerant and Fire extinguishers]
 
1,183.48
1,214.67
Total Scope 2 emissions 
 
3,866.91
3,304.71
Total Scope 1 and Scope 2 emissions per rupee of 
turnover 
Revenue from operations)
 
0.00000013
0.00000014
Total Scope 1 and Scope 2 emissions per rupee of 
turnover adjusted for Purchasing Power Parity (PPP) 
Metric tonnes of CO2 
equivalent/ Rupees
0.0000029
0.0000030
Total Scope 1 and Scope 2 emissions intensity in 
terms of physical output**
-
-
Total Scope 1 and Scope 2 emission intensity 
(optional) – the relevant metric may be selected by 
the entity**
 
-
-
 
 There has not been an external review or analysis conducted to assess various aspects of our operations, performance, or 
compliance with standards or regulations.
 
 
Annual Report 2023-24 | 113
8. 
Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.
Gas (GHG) emissions, several initiatives have been implemented that contribute to environmental sustainability. The Company 
emissions. Additionally, the Company has increased DG exhaust piping to reduce pollution, gifted Borosil stainless steel bottles 
to all employees to reduce plastic waste, and implemented timers for warehouse peripheral street lights to enhance energy 
its subsidiaries efforts to minimize its environmental impact.
9. 
Provide details related to waste management by the entity, in the following format:
Parameter
Plastic waste (A)
73.20
68.40
E-waste (B) 
0
0
Bio-medical waste (C) 
0
0
Construction and demolition waste (D) 
25.00
30.00
Battery waste (E) 
0
0
Radioactive waste (F) 
0
0
Other Hazardous waste. Please Specify, if any. (G) 
0
0
Other Non-hazardous waste generated (H). Please specify, if any. 
292.80
273.60 
Total (A+B + C + D + E + F + G + H)
Waste intensity per rupee of turnover 
(Total waste generated / Revenue from operations)
0.000000010
0.000000011
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP) 
0.00000022
0.00000025
Waste intensity in terms of physical output**
0
0
Waste intensity (optional)–the relevant metric may be selected by the entity**
0
0
(in metric tonnes)
Category of waste
(i) 
Recycled (Oil and Plastic)
0
0
(ii) 
Re-used 
0
0
(iii) Other recovery operations 
0
0
Total 
Category of waste – Oil & Plastic
(i) 
Incineration 
0
0
(ii) 
391.00
372.00
(iii) Other disposal operations
0
0
Total
114 | Annual Report 2023-24
Transforming Healthcare Delivery
 
 No external review or analysis has been conducted to evaluate our operations, performance, or compliance with standards and 
regulations.
 
 
company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to 
manage such wastes.
 
 The Company and its subsidiaries waste management practices are guided by a commitment to sustainability and environmental 
responsibility. However, it is important to note that the Company does not have any manufacturing or processing plants at the 
products and processes, as well as the management of such wastes, are not applicable to the Company’s operations. Despite 
this, the Company and its subsidiaries remain dedicated to implementing and promoting eco-friendly initiatives within its 
scope of activities.
biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / 
clearances are required, please specify details in the following format:
S. 
No.
Location of 
Types of 
operations
The Company and its subsidiaries avoid operating in environmentally fragile or ecologically sensitive areas. This strategic 
choice highlights their commitment to responsible business practices and environmental stewardship, preventing potential 
harm to fragile ecosystems. By selecting locations that are not ecologically sensitive, the Company and its subsidiaries aim 
to minimize their environmental impact and contribute to the preservation of biodiversity and natural habitats.
12. 
 Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current 
Name and brief details of 
EIA 
Date
independent external 
agency (Yes / No)
Results communicated 
in public domain 
(Yes / No)
Relevant 
Not applicable. Following the guidelines of the Ministry of Environment, Forest & Climate Change (MoEF), our operations are 
exempted from the obligation to provide environmental clearance or undergo an Environmental Impact Assessment (EIA).
13. 
 Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention 
and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, and Environment protection act and rules 
thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:
S. 
No.
Specify the law / regulation 
/ guidelines which was not 
complied with
Provide details of the 
regulatory agencies such as pollution 
control boards or by courts
 
if any action
The Company and its subsidiaries have been compliant with all the laws as stated, hence the following categories would not 
be applicable to us.
Annual Report 2023-24 | 115
Leadership Indicators
1. 
Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):
 
For each facility / plant located in areas of water stress, provide the following information:
 
(i) 
Name of the area: Not Applicable in our case.
 
(ii) Nature of operations: Not Applicable in our case.
Parameter
(i) 
Surface water
The Company, along with its subsidiaries 
and warehouses, are located in regions 
where water stress is not a concern. 
This intentional choice of locations 
resource management, ensuring that our 
operations have minimal impact on water-
stressed areas. Consequently, there is no 
water withdrawal.
(ii) 
Groundwater 
(iii) Third party water 
(iv) Seawater / desalinated water 
(v) 
Others 
 
Total volume of water consumption (in kilolitres) 
Water intensity per rupee of turnover (Water consumed / turnover) 
Water intensity 
 – the relevant metric may be selected by the entity 
(i) 
Into Surface water
The Company, along with its subsidiaries 
and warehouses, are located in regions 
where water stress is not a concern. 
This intentional choice of locations 
resource management, ensuring that our 
operations have minimal impact on water-
stressed areas. Consequently, there is no 
water withdrawal.
 
- 
No treatment
 
- 
With treatment – please specify level of treatment 
(ii) 
Into Groundwater
 
- 
No treatment 
 
- 
With treatment – please specify level of treatment 
(iii) Into Seawater 
 
- 
No treatment 
 
- 
With treatment – please specify level of treatment 
(iv) Sent to third-parties
 
- 
No treatment 
 
- 
With treatment – please specify level of treatment
(v) 
Others 
 
- 
No treatment 
 
- 
With treatment – please specify level of treatment
Total water discharged (in kilolitres) 
 
 
 No external review or analysis has been conducted to evaluate our operations, performance, or compliance with standards 
and regulations.
116 | Annual Report 2023-24
Transforming Healthcare Delivery
2. 
Please provide details of total Scope 3 emissions & its intensity, in the following format:
Parameter
Unit
Total Scope 3 emissions 
Metric tonnes of 
 
63,673.16
59,497.87
Total Scope 3 emissions per rupee of turnover**
Metric tonnes of 
Rupees
0.0000016
0.0000018
Total Scope 3 emission intensity (optional) – the relevant 
metric may be selected by the entity**
-
-
-
 
 No external review or analysis has been conducted to evaluate our operations, performance, or compliance with standards and 
regulations.
3. 
 With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of 
activities.
 
 The Company and subsidiaries consciously avoid conducting operations in environmentally fragile or ecologically sensitive 
regions. This strategic decision underscores its dedication to responsible business practices and environmental stewardship, 
aiming to prevent potential harm to delicate ecosystems. By deliberately selecting locations that are not ecologically sensitive, 
the Company and subsidiaries seek to minimize its environmental footprint and support the preservation of biodiversity and 
natural habitats.
well as outcome of such initiatives, as per the following format:
Sr. 
No.
Initiative undertaken
Details of the initiative 
 
Outcome of the initiative
1
Installation of LED Bulbs 
and tube lights in our all 
warehouses.
These efforts are internal to 
the Company, so no web link is 
available for reference.
efforts. By transitioning to LED lighting, we are not 
only reducing our Energy consumption and Carbon 
footprint but also ensuring brighter and safer working 
environments for our employees.
2
Misc. initiatives: 
  Increased DG exhaust 
piping to reduce 
pollution.
  We have gifted Borosil 
stainless steel bottles 
to our all employees to 
reduce plastic waste.
  We also implemented 
Timer for our warehouse 
peripheral street lights.
These efforts are internal to 
the Company, so no web link is 
available for reference.
By increasing DG Exhaust Piping, we have effectively 
reduced pollution levels, contributing to a cleaner 
environment. Providing Borosil stainless steel bottles to 
promoting sustainable practices within our organization. 
Additionally, implementing timers for our Warehouse 
leading to reduced energy consumption and lower 
operational costs. Together, these efforts underscore 
our commitment to environmental sustainability and 
responsible resource management.
Annual Report 2023-24 | 117
5. 
Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link.
 
 The Company has not formulated a Business Continuity and Disaster Management Plan, including its subsidiaries, but intends 
work towards establishing such a plan soon.
adaptation measures have been taken by the entity in this regard?
value chain. However, looking ahead, the Company and its subsidiaries remain committed to proactively assessing potential 
environmental risks and implementing appropriate mitigation or adaptation measures as necessary. We aim to continually 
enhance sustainability practices throughout our operations, ensuring minimal environmental impact across the entire value 
chain.
7. 
 Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental 
impacts.
 
 The percentage of value chain partners assessed for environmental impacts is not applicable, as the Company and its 
and its subsidiaries are dedicated to proactively evaluating potential environmental risks and implementing suitable mitigation 
or adaptation measures in the future.
118 | Annual Report 2023-24
Transforming Healthcare Delivery
PRINCIPLE 7:
SO IN A MANNER THAT IS RESPONSIBLE AND TRANSPARENT
Essential Indicators
Chemists & Druggists (AIOCD). In many of the States, we are also the members of the State Level Chemist and Druggist 
Association.
 
b) 
 List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the 
S. No
Name of the trade and industry 
chambers/ associations
Reach of trade and industry chambers/ 
associations (State/National)
1
AIOCD (All India Organization of Chemists & Druggists)
National
2. 
 Provide details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based 
on adverse orders from regulatory authorities
Name of authority
Brief of the case
Corrective active taken
No issues related to anti-competitive conduct have occurred, and therefore, no corrective actions were required. The 
Company and its subsidiaries maintain a strict adherence to regulatory compliance and fair business practices, ensuring a 
competitive and ethical operating environment.
Leadership Indicators
1. 
Details of public policy positions advocated by the entity:
Sr. 
No.
Public policy 
advocated
Method resorted for 
such advocacy
(Yes/No)
Frequency of Review by Board 
(Annually/ Half yearly/ Quarterly / 
Others – please specify)
 
If available
Nil
Annual Report 2023-24 | 119
Essential Indicators
1. 
 Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current 
Name and Brief details 
SIA 
 
No.
Date of 
independent external 
agency (Yes/No)
Results communicated 
in public domain 
(Yes/No)
Relevant 
Not Applicable
2. 
 Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your 
entity, in the following format:
S. 
No
which R&R is ongoing
State
District
Families (PAFs)
by R&R
Amounts paid to PAFs 
in the FY (in )
Not Applicable
3. 
Describe the mechanisms to receive and redress grievances of the community.
 
 The Company and its subsidiaries have a Grievance Redressal Mechanism in place for its investors. To facilitate this, we have 
a dedicated email ID – investor.grievance@ehspl.com –where investors can submit their grievances available on the website 
and for general contact we have a dedicated email ID – info@enterohealthcare.com.
4. 
Percentage of input material (inputs to total inputs by value) sourced from suppliers:
 
Directly sourced from MSMEs/ small producers
7.29
9.16
Sourced directly from within India**
5. 
 Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a 
permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost
Location
Rural
0.00
0.00
Semi-Urban
1.38
1.48
Urban
12.40
12.13
Metropolitan
86.22
86.39
Leadership Indicators
(Reference: Question 1 of Essential Indicators above):
Corrective action taken
Not Applicable, as the Company and its subsidiaries have not conducted any Social Impact Assessments (SIAs).
by government bodies:
S. No
State
Aspirational District
Amount spent (In )
1
-
-
 12,90,000 (CSR by Chirag Medicare Solutions Private Limited)
2
-
-
 14,20,000 (CSR by Chethana Pharma Private Limited
3
-
-
 7,20,000 (CSR by R S M Pharma Private Limited)
120 | Annual Report 2023-24
Transforming Healthcare Delivery
3. 
(a)  Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising 
marginalized /vulnerable groups? (Yes/No)
 
 
 There is no Preferential Procurement Policy in place to prioritize suppliers from marginalized or vulnerable groups. Our 
procurement strategy focuses on fair and equitable practices. We are committed to fostering an inclusive supply chain 
by ensuring all suppliers have equal opportunities to compete. This approach promotes diversity, innovation, and allows 
us to build strong partnerships based on merit and quality.
 
(b) From which marginalized /vulnerable groups do you procure?
 
 
 Although there is no Preferential Procurement Policy for a particular marginalized /vulnerable groups. Our procurement 
strategy focuses on fair and equitable practices.
 
(c) 
What percentage of total procurement (by value) does it constitute?
 
 
Not Applicable
S No
Intellectual Property based on 
traditional knowledge
Owned/ Acquired 
(Yes/No)
 
(Yes / No)
Basis of calculating 
Not Applicable
5. 
 Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes 
wherein usage of traditional knowledge is involved.
Name of authority
Brief of the case
Corrective Action taken
Not Applicable
S. No
CSR is not applicable to the Company and its subsidiaries except for the following: Chethana Pharma Pvt Ltd, Chirag 
Medicare Solutions Pvt. Ltd and R S M Pharma Pvt. Ltd. However, we contribute funds to the Prime Minister’s National Relief 
Annual Report 2023-24 | 121
RESPONSIBLE MANNER
Essential Indicators
1. 
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
 
 Complaints can be raised by complainant via various methods such as telephone calls received on the Company’s phone no., 
emails at mailbox (info@enterohealthcare.com
Information, For Adverse event (AE) or product complaints related to Entero marketed products, complainant can contact us 
on landline number provided on our website.
2. 
Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:
 
As a percentage to total turnover
Environmental and social parameters relevant to the product
Nil, considering the entity and their subsidiaries business 
operations are not involved in manufacturing/ processing of 
any goods.
Safe and responsible usage
Recycling and/or safe disposal
3. 
Number of consumer complaints in respect of the following:
Remarks
Remarks
Received 
during the Year
Pending resolution 
at end of year
Received 
during the Year
Pending resolution 
at end of year
Data Privacy
No such complaints received for both the reporting years.
Advertising
Cyber-security
Delivery of essential 
services
Restrictive Trade 
Practices
Unfair Trade 
Practices
Other
Total
4. 
Details of instances of product recalls on account of safety issues:
 
Number
Reasons for recall
Voluntary recalls
Not Applicable
Forced recalls
5. 
 Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a 
web-link of the policy.
 
 Yes, the Company has established a comprehensive framework and policy addressing cyber security and data privacy risks. 
This policy outlines protocols and measures to safeguard sensitive information and mitigate cyber threats effectively. It 
emphasizes the importance of data protection, compliance with regulations and the adoption of best practices to ensure the 
6. 
 Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential 
services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action 
taken by regulatory authorities on safety of products / services.
 
Not Applicable, as no such incidents occurred
122 | Annual Report 2023-24
Transforming Healthcare Delivery
7. 
Provide the following information relating to data breaches:
 
a. 
Number of instances of data breaches
 
c. 
Impact, if any, of the data breaches
subsidiaries’ data security measures in safeguarding sensitive information and maintaining the trust of its customers.
Leadership Indicators
1. 
 Channels / platforms where information on products and services of the entity can be accessed (provide web link, if 
available).
https://www.
enterohealthcare.com/. This platform serves as a comprehensive source where customers and stakeholders can explore 
details about the Company’s range of healthcare, pharmaceuticals, surgical and other allied products and services.
2. 
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
educate consumers about safe and responsible product usage or mechanisms to address risks of service disruption. Further 
https://www.enterohealthcare.com/
 
 This platform serves as a comprehensive source where customers and stakeholders can explore details about the Company’s 
range of healthcare, pharmaceuticals, surgical and other allied products and services.
3. 
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
 
 As the Company and its subsidiaries operate in the B2B sector, there is no requirement for mechanisms to inform consumers 
of any risk of disruption or discontinuation of essential services.
4. 
 Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not 
Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to consumer satisfaction relating 
 
(Yes/No)
 
 The Company and its subsidiaries operate as a wholesale distributor of healthcare, pharmaceuticals, surgical and other allied 
products in the B2B sector, doesn’t typically display product information directly to consumers. Further, we have few private 
label surgical products where we display the information as mandated under the local laws. Furthermore, no surveys have been 
conducted regarding consumer satisfaction.
